BD Pays $175M To Resolve Alaris Infusion Pump Financial Fraud Allegations

The settlement with the SEC closes out safety issues around the company’s Alaris infusion pumps. BD reportedly failed to alert investors or the FDA of known problems with the infusion pumps’ software for several years.

BD logo on phone screen against financial tracker background.
(Piotr Swat/Shutterstock)

Becton Dickinson and Company (BD) will pay $175m in civil penalties for allegedly failing to alert investors to safety concerns involving Alaris infusion pumps, the US Securities and Exchange Commission announced on 16 December.

More from Medtech Insight

More from Recalls